Shot in the arm

Lupin is one of India's star pharma success stories. It is the largest manufacturer of tuberculosis drugs in the world, with a presence that spans over 70 countries across the globe. From sales of Rs 2,000 crore ten years back, the company now rings in revenues of over Rs 14,000 crore (FY16). Its ROCE has averaged at 30 per cent during this period - a tough feat for even some of the highest-quality companies to maintain. Why Lupin can continue to be an Unusual Winner Biggest revenue driver ahead and in place: Lupin is the fifth-largest generic company in the US (5.6 per cent market share by prescriptions, IMS Health, Sept